PF-293765

N/A

Report date: 2022/01/14 13:23:58

NME

Base Information

Drug NamePF-293765

Drug Alias NamePF-293765

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionVoltage-gated calcium channel alpha2/delta subunit 1 agonistsVoltage-gated calcium channel alpha2/delta subunit 2 agonists

TargetsVoltage-gated calcium channel alpha2/delta subunit 1Voltage-gated calcium channel alpha2/delta subunit 2

Therapy Area/IndicationsNeuralgia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsNeuralgia

ATC CodeN/A